Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2012

View Archived Issues

Eisai describes new clinical candidate for anxiety and depression

Novel nanotechnology targets t-PA to obstructed blood vessels

Novel DAAO inhibitor shows potential to treat schizophrenia

Small molecule shows potential for as a contraceptive for men

New DNA tests developed for hereditary diseases

Medivir moves MIV-711 into phase Ib testing

Orexo plans NDA for sublingual buprenorphine/naloxone product

Pluristem and BCRT renew 5-year collaboration

New phase III data disclosed on Inavir

Novel prosthetic incorporates retinal code to restore vision

NIH awards HIV vaccine research grants

Aurum Biosciences and Oxygen Biotherapeutics present novel Oxycyte data

Scientists at Novartis synthesize novel CDK9 inhibitors

Investigation at Sphaera Pharma yields new PI3K/mTOR inhibitors

Boehringer Ingelheim Pharma reports new SYK inhibitors

New pim-1/2 inhibitors developed

Novel tyrosine kinase inhibitors patented by Pierre Fabre Medicament

Glymera enters phase IIb trial for uncontrolled type 2 diabetes

FDA extends tofacitinib NDA PDUFA date

FDA to discuss Gattex NDA at advisory committee meeting

Vernalis kicks off receptor occupancy study of V-81444

Foundation Fighting Blindness to fund eight projects for retinal degenerative diseases

NICE issues new guidance on bevacizumab

VolitionRX and Belgian hospital sign agreement for prospective colon cancer trial

Research collaboration begins for delivery of microRNA-based therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...